Gamma-glutamyltransferase is a Strong Predictor of Secondary Sclerosing Cholangitis After Lung Transplantation for COVID-19 ARDS
Overview
Authors
Affiliations
Background: Lung transplantation (LTx) can be considered for selected patients suffering from COVID-19 acute respiratory distress syndrome (ARDS). Secondary sclerosing cholangitis in critically ill (SSC-CIP) patients has been described as a late complication in COVID-19 ARDS survivors, however, rates of SSC-CIP after LTx and factors predicting this detrimental sequela are unknown.
Methods: This retrospective analysis included all LTx performed for post-COVID ARDS at 8 European LTx centers between May 2020 and January 2022. Clinical risk factors for SSC-CIP were analyzed over time. Prediction of SSC-CIP was assessed by ROC-analysis.
Results: A total of 40 patients were included in the analysis. Fifteen patients (37.5%) developed SSC-CIP. GGT at the time of listing was significantly higher in patients who developed SSC-CIP (median 661 (IQR 324-871) vs 186 (109-346); p = 0.001). Moreover, higher peak values for GGT (585 vs 128.4; p < 0.001) and ALP (325 vs 160.2; p = 0.015) were found in the 'SSC' group during the waiting period. Both, GGT at the time of listing and peak GGT during the waiting time, could predict SSC-CIP with an AUC of 0.797 (95% CI: 0.647-0.947) and 0.851 (95% CI: 0.707-0.995). Survival of 'SSC' patients was severely impaired compared to 'no SSC' patients (1-year: 46.7% vs 90.2%, log-rank p = 0.004).
Conclusions: SSC-CIP is a severe late complication after LTx for COVID-19 ARDS leading to significant morbidity and mortality. GGT appears to be a sensitive parameter able to predict SSC-CIP even at the time of listing.
Mahmoud S, Sarkar A, AlMahmoud L, Alladaboina S, Syed L, Yaghmour M Biomedicines. 2025; 13(2).
PMID: 40002841 PMC: 11852956. DOI: 10.3390/biomedicines13020428.
The role of coronary artery disease in lung transplantation: a propensity-matched analysis.
Lusebrink E, Gade N, Seifert P, Ceelen F, Veit T, Fohrer F Clin Res Cardiol. 2024; 113(12):1717-1732.
PMID: 38587564 PMC: 11579179. DOI: 10.1007/s00392-024-02445-y.
Post-COVID-19 cholangiopathy: Systematic review.
Rasheed M, Ballotin V, Bigarella L, Soldera J World J Methodol. 2023; 13(4):296-322.
PMID: 37771872 PMC: 10523251. DOI: 10.5662/wjm.v13.i4.296.
Liu C, Peng J, Liu Y, Peng Y, Kuang Y, Zhang Y J Glob Health. 2023; 13:06027.
PMID: 37449380 PMC: 10346132. DOI: 10.7189/jogh.13.06027.
Liver injury associated with the severity of COVID-19: A meta-analysis.
Yang R, Feng J, Wan H, Zeng X, Ji P, Zhang J Front Public Health. 2023; 11:1003352.
PMID: 36817905 PMC: 9932800. DOI: 10.3389/fpubh.2023.1003352.